Floatz logo

Cosibelimab

Richter's Transformation

TG Therapeutics, Inc.Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
89/ 100

Competitive context

57 Active assets in the Richter's Transformation cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Cosibelimab is also rated in:

skin squamous cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →
skin cancerDormant
CCC
Indicative ·
54 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →